Changing the Standard of Care for Fibroid Treatment and Fertility

Over 5.9% of women (226 million) have Uterine Fibroids world wide

70%-80%

Of women will develop uterine fibroid by the age of 50

20%-30%

Of women with fibroids are symptomatic

>70%

Of women with fibroids are on therapeutic plan

+0%

70%-75%

Of surgeries performed in US are hysterectomies

Symptoms

Menstrual
cramps and pain

Heavy menstrual
bleeding & anemia

Problems with
fertility or pregnancy

Bladder or bowel
symptoms

Uterine Fibroids are benign muscle tumors

Fibroids are classified by their size, shape and location

Myomectomy is The Golden Standard of Care for Uterine Preservation and Future Pregnancy Option.

Minimally Invasive or Laparoscopic Myomectomy Was First Described in the Late 1970’s
It is a Difficult Technique which has not Developed since the early 1990’s

Pressure Induced Fibroid Ischemia

The Empress system is intended to treat symptomatic uterine fibroids, in a laparoscopic procedure, by inducing fibroid tissue ischemia.

Sutures wrapped around the fibroid increases the intra-tumoral pressure which leads to fibroid Ischemia – blockage of intra- and peri-fibroid blood flow and, eventually, necrosis of the fibroid tissue.

Play Video

EMPRESS System Ease-of-Use Features

Published in Reproductive Sciences August 2022

Results from our First In Man Study Demonstrated Safety and Feasibility Of the Empress Procedure

Follow this link for the full article

Pressure-Induced Fibroid Ischemia: First-In-Human Experience with a Novel Device for Laparoscopic Treatment of Symptomatic Uterine Fibroids | SpringerLink

First In Human Feasibility Study Summary

21 uterine fibroids were treated in 16 symptomatic pre-menopausal black women. Pelvic magnetic resonance imaging (MRI) was performed before the procedure, and at 1, 3, 6, and 12 months.
Results suggest the device is safe and can be effective for its intended purpose